Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

New Therapy for the Treatment of Primary Biliary Cholangitis.

Award Number: R43DK134242
ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 05/01/2023
PERIOD OF PERFORMANCE END DATE: 04/30/2025

Group Awards By:

View Award Description

New Therapy for the Treatment of Primary Biliary Cholangitis. - Project Summary Primary biliary cholangitis (PBC) is a chronic disease in which the small bile ducts in the liver become injured and inflamed and eventually destroyed. When bile ducts are depleted, the resulting bile build up results in liver damage, leading to scarring, cirrhosis, and eventually liver failure. Among the common early symptoms of PBC is itchy skin (pruritus), tiredness, abdominal pain, low appetite, weight loss and arthritis. This chronic cholestatic liver disease predominantly affects women in their fourth and sixth decades. Currently therapeutic options to treat PBC are limited and much of the pharmacotherapy is restricted to management of disease symptomology. Lysophosphatidic acid (LPA) acts as a potent signaling molecule with wide-ranging effects on many different target tissues, and is implicated as a mitogen acting mainly through LPAR1 in the development of fibrosis in various organs. LPAR1 is also implicated in the development of arthritis. Many of these observed effects appear to involve LPAR1 activation and modulation of inflammatory responses through numerous signaling molecules including TNFα, IFNγ, IL-17, CTGF and TGFβ. IFNγ and IL-17 are signaling molecules implicated in the development of PBC. Pruritus is a serious symptom associated with PBC which has been linked to Autotaxin, the enzyme responsible for plasma LPA production. LPA may act on neurons through its receptors of which LPAR1 is the principal receptor expressed. Thus, LPAR1 may represent a key locus in the development of both pathologic inflammation and serious quality of life symptoms. Epigen has identified several classes of potent and selective LPAR1 antagonists from which an initial lead compound EPGN696 and backup EPGN2154 have demonstrated pre-clinical efficacy in other disease models. These compounds do not show cholestatic risk in human cellular hepato-toxicity models compared to a clinical compound BMS-986020 which has been withdrawn. We propose to profile the two LPAR1 antagonists for utility in PBC for their ability to modulate key inflammatory signaling molecules IFNγ and IL-17 and itch responses in pre-clinical models. Completion of lead profiling will result in selection of a single lead that will be evaluated in a pre-clinical model of PBC, conducted at University of California Davis. These studies will determine the feasibility of developing a LPAR1 antagonist for treatment of PBC.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2023	EPIGEN BIOSCIENCES INC	6725 MESA RIDGE RD STE 260	SAN DIEGO	CA	92121	SAN DIEGO	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	1	7/28/2025	NEW	$0
														Subtotal = $0

Issue Date FY: 2023 ( Subtotal = $448,110 )
2023	2023	EPIGEN BIOSCIENCES INC	6725 MESA RIDGE RD	SAN DIEGO	CA	92121	SAN DIEGO	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	1	5/31/2023	NEW	$448,110
														Subtotal = $448,110

Grand Total All Awards = $448,110

Top

All Categories

About

Search

Reports

Data Submission

Award Information

New Therapy for the Treatment of Primary Biliary Cholangitis.

Award Number: R43DK134242

ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 05/01/2023

PERIOD OF PERFORMANCE END DATE: 04/30/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer